

**ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034)**  
**24 January 2013**

**PRIMA BIOMED TO HOST INVESTOR DAYS IN AUSTRALIA**

Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) (“Prima”, “the Company”) is pleased to announce upcoming investor days at several major Australian cities in February.

Prima CEO, Matthew Lehman will host the sessions, to be held in Sydney, Melbourne, Brisbane and Perth, in the week commencing 4 February 2013.

Mr. Lehman will provide an update on the Company’s business and attendees will have an opportunity for Q&A.

**Details of dates and venues are provided below.**

- |                  |  |
|------------------|--|
| <b>Perth</b>     | <b>Monday, 4<sup>th</sup> February</b><br>Parmelia Hilton Hotel, 14 Mill St, Perth<br>10.00am – 11.30am local time             |
| <b>Melbourne</b> | <b>Tuesday, 5<sup>th</sup> February</b><br>Westin Melbourne Hotel, 205 Collins St, Melbourne<br>10.30am – 12.00noon local time |
| <b>Brisbane</b>  | <b>Wednesday, 6<sup>th</sup> February</b><br>Hilton Brisbane Hotel, 190 Elizabeth St, Brisbane<br>10.00am – 11.30am local time |
| <b>Sydney</b>    | <b>Thursday, 7<sup>th</sup> February</b><br>Radisson Blu Hotel, 27 O’Connell St, Sydney<br>10.30am – 12.00noon local time      |

Shareholders and other interested parties are kindly requested to help assure appropriate accommodations by sending an RSVP by email to [enquiries@primabiomed.com.au](mailto:enquiries@primabiomed.com.au) and identify the city of attendance by Friday 1<sup>st</sup> February.

ENDS

**About Prima BioMed**

Prima BioMed is a globally active biotechnology company. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.

**For further information please contact:**

**USA Investor/Media:**

Ms. Jessica Brown, Prima BioMed Ltd.  
+1 (919) 710-9061; [jessica.brown@primabiomed.com.au](mailto:jessica.brown@primabiomed.com.au)

**Australia Investor/Media:**

Mr. James Moses, Mandate Corporate  
+61 (0) 420 991 574; [james@mandatecorporate.com.au](mailto:james@mandatecorporate.com.au)

**Europe Investor/Media:**

Mr. Axel Mühlhaus, edicto GmbH  
+49 (0) 69 905505-52; [amuehlhaus@edicto.de](mailto:amuehlhaus@edicto.de)